Oksi, Jarmo http://orcid.org/0000-0002-3331-997X
Aalto, A.
Säilä, P.
Partanen, T.
Anttila, V.-J.
Mattila, E.
Funding for this research was provided by:
University of Turku (UTU) including Turku University Central Hospital
Article History
Received: 23 April 2019
Accepted: 4 July 2019
First Online: 29 July 2019
Compliance with ethical standards
:
: J.O. has been a scientific advisor (review panel or advisory committee) to Astellas, Gilead Sciences Finland, GlaxoSmithKline, MSD Finland, and Unimedic Pharma AB; received lecture honoraria from Gilead Sciences Finland, GlaxoSmithKline, MSD Finland, and Pfizer; and received congress travel/accommodation expenses from Gilead, Janssen, MSD, and Pfizer. A.A. has been a scientific advisor (review panel or advisory committee) to Unimedic Pharma AB and has received lecture honoraria from MSD Finland. P.S. has been a scientific advisor (review panel or advisory committee) to GlaxoSmithKline, received lecture honoraria from MSD Finland, and received congress travel/accommodation expenses from Gilead Sciences Finland. T.P. has received lecture honoraria from MSD Finland. V-J.A. has received lecture honoraria from MSD, Astellas, Roche, Pfizer, BristolMyersSquibb, and Unimedic Pharma AB. E.M. has been a scientific advisor (review panel or advisory committee) and received lecture honoraria from MSD Finland.
: In this retrospective study without patient identifying information, ethical approval is not required according to the law and national ethical guidelines.
: Informed consent was not needed in this study without patient identifying information.